Polar Asset Management Partners Inc. Buys 12,900 Shares of Novo Nordisk A/S (NYSE:NVO)

Polar Asset Management Partners Inc. raised its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 86.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,900 shares of the company's stock after acquiring an additional 12,900 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Novo Nordisk A/S were worth $2,400,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Quadcap Wealth Management LLC boosted its position in Novo Nordisk A/S by 84.4% during the fourth quarter. Quadcap Wealth Management LLC now owns 3,623 shares of the company's stock valued at $312,000 after acquiring an additional 1,658 shares during the last quarter. Quantinno Capital Management LP boosted its position in shares of Novo Nordisk A/S by 4.9% during the 4th quarter. Quantinno Capital Management LP now owns 211,866 shares of the company's stock worth $18,225,000 after purchasing an additional 9,885 shares in the last quarter. Nia Impact Advisors LLC boosted its position in shares of Novo Nordisk A/S by 1.8% during the 4th quarter. Nia Impact Advisors LLC now owns 23,200 shares of the company's stock worth $1,996,000 after purchasing an additional 415 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock worth $537,189,000 after purchasing an additional 2,639,693 shares in the last quarter. Finally, Obermeyer Wealth Partners boosted its position in shares of Novo Nordisk A/S by 13.2% during the 4th quarter. Obermeyer Wealth Partners now owns 130,104 shares of the company's stock worth $11,192,000 after purchasing an additional 15,220 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and an average price target of $135.00.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded up $2.59 during midday trading on Monday, reaching $66.96. The stock had a trading volume of 11,168,331 shares, compared to its average volume of 6,596,989. The stock has a 50-day moving average of $67.31 and a 200-day moving average of $84.19. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market capitalization of $300.49 billion, a price-to-earnings ratio of 20.35, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.